Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

3
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Thoracic Malignancies
Tumour Sub-type
Non-small-cell Lung Cancer
Tumour stage
Metastatic
Combined Agent(s)
Chemotherapy + bevacizumab
Control Arm
Bevacizumab, paclitaxel and carboplatin
Treatment Setting
First-line treatment of metastatic non-squamous NSCLC
Trial Name
IMpower150

Primary Outcome(s)

Primary Outcome(s)
PFS/OS (WT Population)
Evaluated Outcome
OS
Form(s)
Form 2a

Outcome Data

PFS Control
6.8 months
PFS Gain
1.5 months
PFS HR
0.62 (0.52-0.74)
OS Control
14.7 months
OS Gain
4.5 months
OS HR
0.78 (0.64-0.96)
Toxicity Comment
Similar toxicity

Final Score (after adjustments)

Preliminary non-curative score
3
Final non-curative Score
3
Issue date
16.03.2020
Release date
16.03.2020

ChT; chemotherapy; DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PE, point estimate; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings